Skip to main content

23-02-2017 | Multiple myeloma | Article

CARs in the Lead Against Multiple Myeloma

Current Hematologic Malignancy Reports

Authors: Maria Ormhøj, Felipe Bedoya, Matthew J. Frigault, Marcela V. Maus

Publisher: Springer US


The recent clinical success of CD19-directed chimeric antigen receptor (CAR) T cell therapy in chronic and acute leukemia has led to increased interest in broadening this technology to other hematological malignancies and solid tumors. Now, advances are being made using CAR T cell technology to target myeloma antigens such as B cell maturation antigen (BCMA), CD138, and kappa-light chain as well as CD19 on putative myeloma stem cells. To date, only a limited number of multiple myeloma patients have received CAR T cell therapy but preliminary results have been encouraging. In this review, we summarize the recently reported results of clinical trials conducted utilizing CAR T cell therapy in multiple myeloma (MM).

Please log in to get access to this content

Related topics